Companies › Biocon Biologics UK
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bmab1700 PD-1 inhibitor (nivolumab biosimilar) | PDCD1 | Phase 1 | Melanoma | Aug 2027 |
| Bmab1800 PD-1 inhibitor | PDCD1 | Phase 1 | Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07476326 | Bmab1700 | Phase 1 | Melanoma | Oncology | Aug 2027 |
| NCT07581509 | Bmab1800 | Phase 1 | Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) | Oncology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.